In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use. Maher M, Dinneen S. Ann Intern Med 2024;177:JC124.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Maher M, Dinneen S. In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use. Ann Intern Med 2024;177:JC124.
PMID: 39496174